Acumen

Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference

Retrieved on: 
水曜日, 5月 8, 2024
Acumen, Bank, Conference, ABOS

CHARLOTTESVILLE, Va., May 08, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat at the 2024 Bank of America Healthcare Conference on Wednesday, May 15, 2024, at 8:55 a.m. PT (11:55 a.m.

Key Points: 
  • CHARLOTTESVILLE, Va., May 08, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat at the 2024 Bank of America Healthcare Conference on Wednesday, May 15, 2024, at 8:55 a.m. PT (11:55 a.m.
  • ET).
  • The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days.

Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024

Retrieved on: 
火曜日, 5月 7, 2024
Acumen, ABOS, PIN

CHARLOTTESVILLE, Va., May 07, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, today announced that the Company will report first quarter 2024 financial results on Tuesday, May 14, 2024.

Key Points: 
  • CHARLOTTESVILLE, Va., May 07, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, today announced that the Company will report first quarter 2024 financial results on Tuesday, May 14, 2024.
  • The Company will host a conference call and live audio webcast at 8:00 a.m.
  • To participate in the live conference call, please register using this link .
  • After registration, you will be informed of the dial-in numbers including PIN.

3D Systems Announces FDA Clearance for World’s First 3D-Printed PEEK Cranial Implants

Retrieved on: 
月曜日, 4月 15, 2024
Acumen, FDA, 3D Systems, Skull, Food, EXT, Trauma, Surgeon, MED, PEEK, ISO, 3D, Carbon, University Hospital of Basel, ROCK, SVP, Spine, Patient, Neurosurgery, Pyridinium p-toluenesulfonate, I4, Database, Health, VSP, Medical device

VSP PEEK Cranial Implant includes a complete FDA-cleared workflow comprising segmentation and 3D modeling software, the 3D Systems EXT 220 MED 3D printer, Evonik VESTAKEEP ® i4 3DF PEEK (polyetheretherketone), and a pre-defined production process.

Key Points: 
  • VSP PEEK Cranial Implant includes a complete FDA-cleared workflow comprising segmentation and 3D modeling software, the 3D Systems EXT 220 MED 3D printer, Evonik VESTAKEEP ® i4 3DF PEEK (polyetheretherketone), and a pre-defined production process.
  • “Receiving FDA clearance for our VSP PEEK Cranial Implant solution is a significant milestone in our journey.
  • With this FDA clearance, we are now able to bring VSP PEEK Cranial Implant to the U.S. — setting a new standard of excellence for these procedures.
  • This FDA clearance enables 3D Systems to significantly expand its PEEK product portfolio through the EXT 220 MED platform.

Edwards Lifesciences Reports First Quarter Results

Retrieved on: 
木曜日, 4月 25, 2024
Managed Care, Biotechnology, Health, Cardiology, Acumen, Mortality, FDA, Critical care, Investment, Pulmonary artery catheter, Research, Trial of the century, Aortic stenosis, Growth, Ultra, U.S. FDA, ICU, TAVR, Patient, PROGRESS, EPS, Hospital, PASCAL, Quality of life, M3, Heart failure, Pharmaceutical industry

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended March 31, 2024.

Key Points: 
  • Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended March 31, 2024.
  • Surgical Structural Heart sales for the quarter were $266 million, which grew 7%, or 8% on a constant currency basis.
  • For the quarter, the adjusted gross profit margin was 76.0%, compared to 77.5% in the same period last year.
  • For the second quarter of 2024, the company projects total sales to be between $1.62 and $1.70 billion, and adjusted EPS of $0.67 to $0.71.

New York Car Dealership Enlists Energy Toolbase and Socomec for Microgrid-Capable Energy Storage System

Retrieved on: 
水曜日, 4月 24, 2024
Acumen, HES, Solar energy, Accounting, Consolidated Edison, Electricity, ESS, Entrepreneurship, EV, GMC, DLRP, Renewable energy

BEDFORD HILLS, N.Y., April 24, 2024 /PRNewswire/ -- Energy Toolbase , Socomec, and Sprocket Power have deployed an energy storage system (ESS) at an expansive New York car dealership to provide microgrid capabilities, reduce demand charges, and participate in the state's demand response programs.

Key Points: 
  • BEDFORD HILLS, N.Y., April 24, 2024 /PRNewswire/ -- Energy Toolbase , Socomec, and Sprocket Power have deployed an energy storage system (ESS) at an expansive New York car dealership to provide microgrid capabilities, reduce demand charges, and participate in the state's demand response programs.
  • Sprocket Power spearheaded the installation of a 100kW/186kWh energy storage system at the Vail Buick GMC dealership in Bedford Hills, New York.
  • The system, equipped with a Socomec HES L unit integrated with Acumen EMS™ controls software, complements the dealership's existing solar infrastructure.
  • Historically, New York's grid has encountered significant strain, prompting the strategic decision to incorporate solar energy storage to support electric vehicle (EV) chargers installed at the dealership.

Energy Toolbase Deploys 2-Megawatt Energy Storage System with Socomec Providing Critical Load Backup at California Mall

Retrieved on: 
木曜日, 4月 11, 2024
Acumen, Solar System, Partnership, ESS, Power, BPI, Renewable energy

Blue Sky Utility , a renewable energy developer based in California, sourced the ESS from Energy Toolbase.

Key Points: 
  • Blue Sky Utility , a renewable energy developer based in California, sourced the ESS from Energy Toolbase.
  • Installed by BPi , a Napa-based solar energy contractor, are two Socomec HES L batteries integrated with Acumen EMS controls software, boasting a total energy storage capacity of 500kW/2,372kWh.
  • The Socomec systems feature an island mode capability, ensuring critical load backup during utility outages, and can fully charge from the existing solar array.
  • "Energy Toolbase is excited to once again partner with the Blue Sky Utility team to bring more energy storage to California," said Kevin Mulvey, Vice President of Operations at Energy Toolbase.

Reuters Publishes Pulsar Helium Film Documentary

Retrieved on: 
金曜日, 4月 5, 2024
Acumen, MRI, PLSR, History, News, Pulsar, Jet stream, Reuters

VANCOUVER, British Columbia, April 05, 2024 (GLOBE NEWSWIRE) -- Pulsar Helium Inc. (TSXV:PLSR | OTCQB:PSRHF) (“Pulsar” or the “Company”) is pleased to announce that a recently filmed documentary featuring Pulsar’s team onsite during the drilling of the Jetstream #1 appraisal well at the Topaz helium project (USA, MN) has been published as a dedicated segment on reuters.com.

Key Points: 
  • VANCOUVER, British Columbia, April 05, 2024 (GLOBE NEWSWIRE) -- Pulsar Helium Inc. (TSXV:PLSR | OTCQB:PSRHF) (“Pulsar” or the “Company”) is pleased to announce that a recently filmed documentary featuring Pulsar’s team onsite during the drilling of the Jetstream #1 appraisal well at the Topaz helium project (USA, MN) has been published as a dedicated segment on reuters.com.
  • Pulsar, whose assets are in the USA and Greenland, is the first private helium exploration company to work directly with the Reuters news network to highlight the critical importance of ‘safe jurisdiction’ domestically sourced primary helium.
  • Almost all electronic devices require helium during manufacture, key lifesaving medical services including MRI scanners and breathing gasses also rely on a steady and reliable source of helium.
  • Since this documentary was filmed Pulsar has identified helium contents of up to 13.8% at Topaz, making it one of the highest-grade discoveries in history.

Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease

Retrieved on: 
木曜日, 4月 4, 2024
Acumen, Patient, CGMP, Penile spines, Fine chemical

The agreement covers the manufacture of sabirnetug (ACU193), an antibody targeting toxic soluble AβOs for the treatment of AD, for clinical development and commercialization, if approved.

Key Points: 
  • The agreement covers the manufacture of sabirnetug (ACU193), an antibody targeting toxic soluble AβOs for the treatment of AD, for clinical development and commercialization, if approved.
  • Under the terms of the agreement, Lonza will manufacture the sabirnetug drug substance at its next-generation, manufacturing facility in Portsmouth, New Hampshire (US), equipped with 2,000L single-use bioreactors.
  • Acumen will leverage Lonza’s regulatory expertise, extensive experience in antibody manufacturing, and global manufacturing network from 2,000L to 20,000L.
  • Sabirnetug is the first humanized monoclonal antibody to demonstrate selective target engagement of AβOs in a Phase 1 first-in-human study.

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024

Retrieved on: 
火曜日, 3月 19, 2024
Acumen, ABOS, PIN

CHARLOTTESVILLE, Va., March 19, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, today announced that the Company will report fourth quarter and year-end 2023 financial results on Tuesday, March 26, 2024.

Key Points: 
  • CHARLOTTESVILLE, Va., March 19, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, today announced that the Company will report fourth quarter and year-end 2023 financial results on Tuesday, March 26, 2024.
  • The Company will host a conference call and live audio webcast at 8:00 a.m.
  • ET to provide a business and financial update.
  • After registration, you will be informed of the dial-in numbers including PIN.

Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days

Retrieved on: 
火曜日, 3月 12, 2024
Acumen, ABOS

CHARLOTTESVILLE, Va., March 12, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat as part of the Stifel 2024 CNS Days on Tuesday, March 19, 2024, at 12:00 p.m.

Key Points: 
  • CHARLOTTESVILLE, Va., March 12, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat as part of the Stifel 2024 CNS Days on Tuesday, March 19, 2024, at 12:00 p.m.
  • ET.
  • The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days.